Trevor J. Del Castillo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Trevor J. Del Castillo has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Robert M. Waymouth
Department of Chemistry Stanford University California USA
4 shared publications Ole A. W. Haabeth
Division of Oncology, Department of Medicine, Stanford Cancer Institute, Stanford University, Stanford, California 94305, United States
2 shared publications- Paul A. Wender
Stanford University
2 shared publications Rebecca L. McClellan
Department of Chemistry
2 shared publicationsAdrienne Sallets
Division of Oncology, Department of Medicine, Stanford Cancer Institute, Stanford University, Stanford, California 94305, United States
1 shared publication- Daniel P. Marron
Department of Chemistry, Stanford University, Stanford, California 94306, United States
1 shared publication
Latest Publications
- 6 November 2025
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 19 (45) , 38954-38969
The Structure and Morphology of Single-Component Oligomeric RNA Delivery Vectors Derived from Amphiphilic Charge-Altering Releasable Transporters
Advances in nucleic acid delivery have inspired efforts to mimic the function of natural viruses through the development of self-assemblies capable of gene delivery. RNA assemblies based on amphiphilic polymers are emerging as alternatives to lipid nanoparticles, but the factors that govern the self-assembly of RNA with polymeric amphiphiles are poorly understood. Here, we describe the structure of coacervate nanoparticle assemblies derived from RNA and synthetic cationic polymer amphiphiles based on Charge Altering Releasable Transporters (CARTs). CARTs are effective gene delivery agents derived from block copolymer amphiphiles. Cryogenic electron microscopy and tomography (CryoEM, CryoET), small-angle neutron scattering (SANS) and small-angle X-ray scattering (SAXS) reveal that the self-assembly of RNA with low molar mass (≤10,000 g/mol) CART amphiphiles generates nanoparticles with disordered bicontinuous internal morphologies composed of interpenetrating lipid and aqueous coacervate domains. Systematic variation of the cationic and lipophilic blocks in low molar mass CART amphiphiles demonstrates that both the internal domain spacings (6 to 8 nm) and the order of the resulting bicontinuous CART-RNA assemblies depend on the CART chemical structure and the oligonucleotide cargo (mRNA vs siRNA). Notably, the presence of RNA drives the formation of bicontinuous morphologies. In contrast, CART/RNA assemblies with higher molar mass (≥28,000 g/mol) CART amphiphiles fail to generate bicontinuous assemblies, instead yielding aggregates composed of particles approximately 10 to 20 nm in diameter. This work illuminates the internal morphologies of RNA assemblies with synthetic block copolymer amphiphiles, with implications for the rational design of polymer-based RNA delivery systems.
- 6 November 2025
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 19 (45) , 38954-38969
The Structure and Morphology of Single-Component Oligomeric RNA Delivery Vectors Derived from Amphiphilic Charge-Altering Releasable Transporters
Advances in nucleic acid delivery have inspired efforts to mimic the function of natural viruses through the development of self-assemblies capable of gene delivery. RNA assemblies based on amphiphilic polymers are emerging as alternatives to lipid nanoparticles, but the factors that govern the self-assembly of RNA with polymeric amphiphiles are poorly understood. Here, we describe the structure of coacervate nanoparticle assemblies derived from RNA and synthetic cationic polymer amphiphiles based on Charge Altering Releasable Transporters (CARTs). CARTs are effective gene delivery agents derived from block copolymer amphiphiles. Cryogenic electron microscopy and tomography (CryoEM, CryoET), small-angle neutron scattering (SANS) and small-angle X-ray scattering (SAXS) reveal that the self-assembly of RNA with low molar mass (≤10,000 g/mol) CART amphiphiles generates nanoparticles with disordered bicontinuous internal morphologies composed of interpenetrating lipid and aqueous coacervate domains. Systematic variation of the cationic and lipophilic blocks in low molar mass CART amphiphiles demonstrates that both the internal domain spacings (6 to 8 nm) and the order of the resulting bicontinuous CART-RNA assemblies depend on the CART chemical structure and the oligonucleotide cargo (mRNA vs siRNA). Notably, the presence of RNA drives the formation of bicontinuous morphologies. In contrast, CART/RNA assemblies with higher molar mass (≥28,000 g/mol) CART amphiphiles fail to generate bicontinuous assemblies, instead yielding aggregates composed of particles approximately 10 to 20 nm in diameter. This work illuminates the internal morphologies of RNA assemblies with synthetic block copolymer amphiphiles, with implications for the rational design of polymer-based RNA delivery systems.
- 30 March 2023
- Published by American Chemical Society (ACS) in Bioconjugate Chemistry
- Vol. 34 (4) , 673-685
Lysine-Derived Charge-Altering Releasable Transporters: Targeted Delivery of mRNA and siRNA to the Lungs
Targeted delivery of nucleic acid therapeutics to the lungs could transform treatment options for pulmonary disease. We have previously developed oligomeric charge-altering releasable transporters (CARTs) for in vivo mRNA transfection and demonstrated their efficacy for use in mRNA-based cancer vaccination and local immunomodulatory therapies against murine tumors. While our previously reported glycine-based CART-mRNA complexes (G-CARTs/mRNA) show selective protein expression in the spleen (mouse, >99%), here, we report a new lysine-derived CART-mRNA complex (K-CART/mRNA) that, without additives or targeting ligands, shows selective protein expression in the lungs (mouse, >90%) following systemic IV administration. We further show that by delivering siRNA using the K-CART, we can significantly decrease expression of a lung-localized reporter protein. Blood chemistry and organ pathology studies demonstrate that K-CARTs are safe and well-tolerated. We report on the new step economical, organocatalytic synthesis (two steps) of functionalized polyesters and oligo-carbonate-co-α-aminoester K-CARTs from simple amino acid and lipid-based monomers. The ability to direct protein expression selectively in the spleen or lungs by simple, modular changes to the CART structure opens fundamentally new opportunities in research and gene therapy.
- 30 March 2023
- Published by American Chemical Society (ACS) in Bioconjugate Chemistry
- Vol. 34 (4) , 673-685
Lysine-Derived Charge-Altering Releasable Transporters: Targeted Delivery of mRNA and siRNA to the Lungs
Targeted delivery of nucleic acid therapeutics to the lungs could transform treatment options for pulmonary disease. We have previously developed oligomeric charge-altering releasable transporters (CARTs) for in vivo mRNA transfection and demonstrated their efficacy for use in mRNA-based cancer vaccination and local immunomodulatory therapies against murine tumors. While our previously reported glycine-based CART-mRNA complexes (G-CARTs/mRNA) show selective protein expression in the spleen (mouse, >99%), here, we report a new lysine-derived CART-mRNA complex (K-CART/mRNA) that, without additives or targeting ligands, shows selective protein expression in the lungs (mouse, >90%) following systemic IV administration. We further show that by delivering siRNA using the K-CART, we can significantly decrease expression of a lung-localized reporter protein. Blood chemistry and organ pathology studies demonstrate that K-CARTs are safe and well-tolerated. We report on the new step economical, organocatalytic synthesis (two steps) of functionalized polyesters and oligo-carbonate-co-α-aminoester K-CARTs from simple amino acid and lipid-based monomers. The ability to direct protein expression selectively in the spleen or lungs by simple, modular changes to the CART structure opens fundamentally new opportunities in research and gene therapy.
- 19 January 2023
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 145 (4) , 2282-2293
Mechanism-Guided Design of Robust Palladium Catalysts for Selective Aerobic Oxidation of Polyols
The palladium complex [(L1)Pd(mu-OAc)]2[OTf]2 (L1 = neocuproine) is a selective catalyst for the aerobic oxidation of vicinal polyols to a-hydroxyketones, but competitive oxidation of the ligand methyl groups limits the turnover number and necessitates high Pd loadings. Replacement of the neocuproine ligand with 2,2 '-biquinoline ligands was investigated as a strategy to improve catalyst performance and explore the relationship between ligand structure and reactivity. Evaluation of [(L2)Pd(mu- OAc)]2[OTf]2 (L2 = 2,2 '-biquinoline) as a catalyst for aerobic alcohol oxidation revealed a threefold enhancement in turnover number relative to the neocuproine congener, but a much slower rate. Mechanistic studies indicated that the slow rates observed with L2 were a consequence of precipitation of an insoluble trinuclear palladium species-(L2Pd)3(mu-O)22+-formed during catalysis and characterized by high-resolution electrospray ionization mass spectrometry. Density functional theory was used to predict that a sterically modified biquinoline ligand, L3 = 7,7 '-di-tert-butyl-2,2 '-biquinoline, would disfavor the formation of the trinuclear (LPd)3(mu-O)22+ species. This design strategy was validated as catalytic aerobic oxidation with [(L3)Pd(mu-OAc)]2[OTf]2 is both robust and rapid, marrying the kinetics of the parent L1-supported system with the high aerobic turnover numbers of the L2 supported system. Changes in ligand structure were also found to modulate regioselectivity in the oxidation of complex glycoside substrates, providing new insights into structure-selectivity relationships with this class of catalysts.
- 19 January 2023
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 145 (4) , 2282-2293
Mechanism-Guided Design of Robust Palladium Catalysts for Selective Aerobic Oxidation of Polyols
The palladium complex [(L1)Pd(mu-OAc)]2[OTf]2 (L1 = neocuproine) is a selective catalyst for the aerobic oxidation of vicinal polyols to a-hydroxyketones, but competitive oxidation of the ligand methyl groups limits the turnover number and necessitates high Pd loadings. Replacement of the neocuproine ligand with 2,2 '-biquinoline ligands was investigated as a strategy to improve catalyst performance and explore the relationship between ligand structure and reactivity. Evaluation of [(L2)Pd(mu- OAc)]2[OTf]2 (L2 = 2,2 '-biquinoline) as a catalyst for aerobic alcohol oxidation revealed a threefold enhancement in turnover number relative to the neocuproine congener, but a much slower rate. Mechanistic studies indicated that the slow rates observed with L2 were a consequence of precipitation of an insoluble trinuclear palladium species-(L2Pd)3(mu-O)22+-formed during catalysis and characterized by high-resolution electrospray ionization mass spectrometry. Density functional theory was used to predict that a sterically modified biquinoline ligand, L3 = 7,7 '-di-tert-butyl-2,2 '-biquinoline, would disfavor the formation of the trinuclear (LPd)3(mu-O)22+ species. This design strategy was validated as catalytic aerobic oxidation with [(L3)Pd(mu-OAc)]2[OTf]2 is both robust and rapid, marrying the kinetics of the parent L1-supported system with the high aerobic turnover numbers of the L2 supported system. Changes in ligand structure were also found to modulate regioselectivity in the oxidation of complex glycoside substrates, providing new insights into structure-selectivity relationships with this class of catalysts.
- 24 June 2022
- Published by American Chemical Society (ACS) in Biomacromolecules
- Vol. 23 (7) , 2976-2988
Fingolimod-Conjugated Charge-Altering Releasable Transporters Efficiently and Specifically Deliver mRNA to Lymphocytes In Vivo and In Vitro
Charge-altering releasable transporters (CARTs) are a class of oligonucleotide delivery vehicles shown to be effective for delivery of messenger RNA (mRNA) both in vitro and in vivo. Here, we exploited the chemical versatility of the CART synthesis to generate CARTs containing the small-molecule drug fingolimod (FTY720) as a strategy to increase mRNA delivery and expression in lymphocytes through a specific ligand−receptor interaction. Fingolimod is an FDA-approved small-molecule drug that, upon in vivo phosphorylation, binds to the sphingosine-1-phosphate receptor 1 (S1P1), which is highly expressed on lymphocytes. Compared to its non-fingolimod-conjugated analogue, the fingolimod-conjugated CART achieved superior transfection of activated human and murine T and B lymphocytes in vitro. The higher transfection of the fingolimod-conjugated CARTs was lost when cells were exposed to a free fingolimod before transfection. In vivo, the fingolimod-conjugated CART showed increased mRNA delivery to marginal zone B cells and NK cells in the spleen, relative to CARTs lacking fingolimod. Moreover, fingolimod-CART-mediated mRNA delivery induces peripheral blood T-cell depletion similar to free fingolimod. Thus, we show that functionalization of CARTs with a pharmacologically validated small molecule can increase transfection of a cellular population of interest while conferring some of the targeting properties of the conjugated small molecule to the CARTs.
- 24 June 2022
- Published by American Chemical Society (ACS) in Biomacromolecules
- Vol. 23 (7) , 2976-2988
Fingolimod-Conjugated Charge-Altering Releasable Transporters Efficiently and Specifically Deliver mRNA to Lymphocytes In Vivo and In Vitro
Charge-altering releasable transporters (CARTs) are a class of oligonucleotide delivery vehicles shown to be effective for delivery of messenger RNA (mRNA) both in vitro and in vivo. Here, we exploited the chemical versatility of the CART synthesis to generate CARTs containing the small-molecule drug fingolimod (FTY720) as a strategy to increase mRNA delivery and expression in lymphocytes through a specific ligand−receptor interaction. Fingolimod is an FDA-approved small-molecule drug that, upon in vivo phosphorylation, binds to the sphingosine-1-phosphate receptor 1 (S1P1), which is highly expressed on lymphocytes. Compared to its non-fingolimod-conjugated analogue, the fingolimod-conjugated CART achieved superior transfection of activated human and murine T and B lymphocytes in vitro. The higher transfection of the fingolimod-conjugated CARTs was lost when cells were exposed to a free fingolimod before transfection. In vivo, the fingolimod-conjugated CART showed increased mRNA delivery to marginal zone B cells and NK cells in the spleen, relative to CARTs lacking fingolimod. Moreover, fingolimod-CART-mediated mRNA delivery induces peripheral blood T-cell depletion similar to free fingolimod. Thus, we show that functionalization of CARTs with a pharmacologically validated small molecule can increase transfection of a cellular population of interest while conferring some of the targeting properties of the conjugated small molecule to the CARTs.